Intra-Cellular Therapies, Inc. (ITCI)

Intra-Cellular Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-74.68	-139.67	-256.26	-284.13	-227.01
Depreciation & Amortization	0.51	0.53	0.66	0.53	0.53
Loss (Gain) From Sale of Investments	-9.03	-8.4	0.45	-4.08	-0.65
Stock-Based Compensation	64.12	52.92	43.1	34.48	24.33
Change in Accounts Receivable	-52.48	-38.83	-55.03	-9.39	-10.77
Change in Inventory	-14.91	-26.35	-15.97	-0.89	-7.06
Change in Accounts Payable	14.62	1.06	1.7	3.19	-1.92
Change in Other Net Operating Assets	-1.33	34.54	11.17	0.74	-7.8
Operating Cash Flow	-73.18	-124.2	-270.19	-259.54	-230.07
Capital Expenditures	-0.32	-0.27	-0.78	-0.33	-0.27
Investment in Securities	-334.83	105.81	-127.6	280.67	-480.03
Investing Cash Flow	-335.15	105.54	-128.37	280.34	-480.3
Issuance of Common Stock	567.51	17.81	455.16	11.52	664.18
Financing Cash Flow	567.51	17.81	455.16	11.52	664.18
Net Cash Flow	159.18	-0.85	56.6	32.32	-46.19
Free Cash Flow	-73.5	-124.47	-270.96	-259.87	-230.34
Free Cash Flow Margin	-10.79%	-26.80%	-108.25%	-310.10%	-1009.69%
Free Cash Flow Per Share	-0.71	-1.30	-2.88	-3.20	-3.27
Cash Income Tax Paid	1.82	0.16	0.01	0.01	0
Levered Free Cash Flow	-63.55	-28.97	-180.85	-150.04	-148.8
Unlevered Free Cash Flow	-63.55	-28.97	-180.85	-150.04	-148.8
Change in Net Working Capital	54.9	-17.46	59.06	6.18	28.87

Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q